论文部分内容阅读
目的探讨联合应用肿瘤浸润性淋巴细胞（ｔｕｍｏｒｉｎｆｉｔｒａｔｉｎｇｌｙｍｐｈｏｃｙｔｅｓ，ＴＩＬ）和重组白细胞介素２（ｒＩＬ２）治疗对原发性肝细胞癌（ｐｒｉｍａｒｙｈｅｐａｔｏｃｅｌｕｌａｒｃａｒｃｉｎｏｍａ，ＰＨＣＣ）术后患者细胞免疫功能的影响和其临床疗效。方法对１６例ＰＨＣＣ术后患者进行了ＴＩＬ和ｒＩＬ２治疗，１２例从肝动脉插管输入，４例从门静脉插管输入。结果ＴＩＬ治疗后１６例患者外周血白细胞介素２（ＩＬ２），Ｔ细胞亚群及比率均有不同程度上升；肿瘤坏死因子（ＴＮＦ），白细胞介素６（ＩＬ６）多有不同程度下降。随访６～２４个月，１４例肝癌根治性切除术患者，肿瘤无复发迹象，１例肝癌根治切除术患者ＴＮＦ上升了８ＩＵ，该患者治疗８个月后死于肝功能衰竭；１例肝癌姑息性切除，残癌无水酒精注射病人，ＴＩＬ治疗１８个月后肿瘤直径扩大２ｃｍ。结论ＴＩＬ治疗对提高ＰＨＣＣ术后患者抗肿瘤细胞免疫功能，防止肿瘤复发，抑制残瘤生长，延长患者生存期具有一定作用。
Objective To investigate the effect of combination therapy with tumor infiltrating lymphocytes (TIL) and recombinant interleukin 2 (rIL2) on cellular immune function in patients with primary hepatocellular carcinoma (PHCC) and its clinical efficacy . Methods TIL and rIL2 treatment were performed on 16 patients with PHCC after operation. Twelve patients received input from the hepatic artery and 4 patients received input from the portal vein. Results After TIL treatment, peripheral blood interleukin 2 (IL-2), T lymphocyte subsets and ratio increased in different degrees in 16 patients; tumor necrosis factor (TNF) and interleukin 6 (IL-6) were different. The degree of decline. After 6 to 24 months follow-up, 14 patients with hepatocellular carcinoma undergoing radical resection had no evidence of recurrence. One patient with radical resection of hepatocellular carcinoma had an increase in TNF of 8 IU. He died of hepatic failure after 8 months of treatment. Hepatoma palliative occurred in 1 patient. Surgical resection and residual ethanol injection in patients with residual alcohol, tumor diameter increased by 2cm after TIL treatment for 18 months. Conclusion TIL treatment has an effect on improving the anti-tumor immune function of patients after PHCC, preventing tumor recurrence, inhibiting the growth of residual tumors, and prolonging the survival period of patients.